AAP
ELDN icon

Arax Advisory Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Arax Advisory Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157 Buy
+23
New +$54 ﹤0.01% 3572
2025
Q4 		– Sell
-152
Closed -$393 – 4209
2025
Q3 		$393 Buy
+152
New +$444 ﹤0.01% 3392

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Arax Advisory Partners's ELDN Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Eledon Pharmaceuticals (ELDN) in Q1 2026: 23 shares worth $157. The stake represents ﹤0.01% of the portfolio and ranks #3572 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ELDN as recently as Q3 2025.

Arax Advisory Partners first reported a position in ELDN in Q3 2025 and has held it in 2 quarters since. The position peaked at $393 in Q3 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Arax Advisory Partners held 23 shares of Eledon Pharmaceuticals worth $157 as of Q1 2026.
  • Eledon Pharmaceuticals was a new Arax Advisory Partners position in Q1 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3572 holding.
  • Arax Advisory Partners first reported a position in Eledon Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Eledon Pharmaceuticals position peaked at $393 in Q3 2025.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.